# A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

> **NCT07668388** · PHASE2 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 300 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** UBT251
- **DRUG:** UBT251 Placebo
- **DRUG:** Semaglutide
- **DRUG:** Semaglutide Placebo

## Key facts

- **NCT ID:** NCT07668388
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2027-10-04
- **Final completion:** 2027-11-15
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668388, "A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*